ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
The use of two medicines together (combination therapies) for previously [...]
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
Brain metastases resulting from the spread of renal cell carcinoma [...]
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
Data from the CheckMate-920 study on the safety and effectiveness [...]
The recent phase II KEYNOTE-427 study investigated the efficacy and [...]
Four-year follow up data are now available from the CheckMate [...]
Further results from the ongoing CheckMate 214 phase III study [...]
Results from the phase II FRACTION-RCC clinical trial to assess [...]
Two studies were presented during the 2020 American Society of [...]